NCT02706067View on ClinicalTrials.gov

Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Obesity
Interventions
DRUG

Orlistat

Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.

Trial Locations (1)

1211

Geneva

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02706067 - Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults | Biotech Hunter | Biotech Hunter